Relevance,RGD ID,Symbol,Name,LOD,P Value,Trait,Sub Trait,Chr,Start,Stop,Species,Annotations,Match,Type 1000,61475,Aia2,Adjuvant induced arthritis QTL 2,5.8,,joint integrity trait (VT:0010548),joint inflammation composite score (CMO:0000919),4,37685175,73066691,Rat,n/a,region,qtl 1000,61476,Aia3,Adjuvant induced arthritis QTL 3,3.9,,joint integrity trait (VT:0010548),joint inflammation composite score (CMO:0000919),4,86532519,131532519,Rat,n/a,region,qtl 1000,738031,Alc14,Alcohol consumption QTL 14,7.6,0.00003,consumption behavior trait (VT:0002069),ethanol drink intake rate to body weight ratio (CMO:0001616),4,58640017,154427984,Rat,n/a,region,qtl 1000,738016,Alc16,Alcohol consumption QTL 16,3.6,0.00015,consumption behavior trait (VT:0002069),ethanol drink intake rate to body weight ratio (CMO:0001616),4,58640017,154427984,Rat,n/a,region,qtl 1000,70200,Alc18,Alcohol consumption QTL 18,9.2,,drinking behavior trait (VT:0001422),ethanol intake volume to total fluid intake volume ratio (CMO:0001591),4,55324953,148360954,Rat,n/a,region,qtl 1000,1641833,Alc21,Alcohol consumption QTL 21,8.6,0.0001,drinking behavior trait (VT:0001422),ethanol drink intake rate (CMO:0001407),4,55375865,125671711,Rat,n/a,region,qtl 1000,1641919,Alc22,Alcohol consumption QTL 22,,0.0005,drinking behavior trait (VT:0001422),ethanol drink intake rate (CMO:0001407),4,62947687,125671711,Rat,n/a,region,qtl 1000,634335,Anxrr16,Anxiety related response QTL 16,7.22,,locomotor behavior trait (VT:0001392),number of entries into a discrete space in an experimental apparatus (CMO:0000960),4,94893247,168046938,Rat,n/a,region,qtl 1000,2313401,Anxrr27,Anxiety related response QTL 27,,,aggression-related behavior trait (VT:0015014),tameness/aggressiveness composite score (CMO:0002136),4,33637803,61708341,Rat,n/a,region,qtl 1000,6478684,Anxrr30,Anxiety related response QTL 30,,0.00087,defecation behavior trait (VT:0010462),defecation rate (CMO:0000998),4,63812687,108812687,Rat,n/a,region,qtl 1000,6478724,Anxrr35,Anxiety related response QTL 35,,0.00449,defecation behavior trait (VT:0010462),defecation measurement (CMO:0000997),4,8052189,53052189,Rat,n/a,region,qtl 1000,6478743,Anxrr40,Anxiety related response QTL 40,,0.83076,defecation behavior trait (VT:0010462),defecation rate (CMO:0000998),4,63812687,108812687,Rat,n/a,region,qtl 1000,6478760,Anxrr45,Anxiety related response QTL 45,,0.06717,locomotor behavior trait (VT:0001392),amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958),4,110702761,155702761,Rat,n/a,region,qtl 1000,6478763,Anxrr46,Anxiety related response QTL 46,,0.07428,locomotor behavior trait (VT:0001392),amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958),4,110702761,155702761,Rat,n/a,region,qtl 1000,6478766,Anxrr47,Anxiety related response QTL 47,,0.09637,locomotor behavior trait (VT:0001392),number of entries into a discrete space in an experimental apparatus (CMO:0000960),4,8052189,53052189,Rat,n/a,region,qtl 1000,6478769,Anxrr48,Anxiety related response QTL 48,,0.02514,locomotor behavior trait (VT:0001392),amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958),4,8052189,53052189,Rat,n/a,region,qtl 1000,6478772,Anxrr49,Anxiety related response QTL 49,,0.15488,defecation behavior trait (VT:0010462),defecation rate (CMO:0000998),4,63812687,108812687,Rat,n/a,region,qtl 1000,6478778,Anxrr51,Anxiety related response QTL 51,,0.25384,locomotor behavior trait (VT:0001392),"measurement of voluntary locomotion into, out of or within a discrete space in an experimental apparatus (CMO:0000957)",4,123587009,168587009,Rat,n/a,region,qtl 1000,12798519,Anxrr54,Anxiety related response QTL 54,2.54,0.05,locomotor behavior trait (VT:0001392),"distance moved per unit of time into, out of or within a discrete space in an experimental apparatus (CMO:0001493)",4,112807675,157807675,Rat,n/a,region,qtl 1000,12798520,Anxrr55,Anxiety related response QTL 55,4.45,0.01,locomotor behavior trait (VT:0001392),number of rearing movements with lid-pushing in an experimental apparatus (CMO:0002715),4,29549895,112807890,Rat,n/a,region,qtl 1000,12798523,Anxrr56,Anxiety related response QTL 56,2.83,0.05,locomotor behavior trait (VT:0001392),amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958),4,86312589,147702403,Rat,n/a,region,qtl 1000,12798527,Anxrr58,Anxiety related response QTL 58,4.11,0.05,locomotor behavior trait (VT:0001392),"distance moved per unit of time into, out of or within a discrete space in an experimental apparatus (CMO:0001493)",4,120318422,146087100,Rat,n/a,region,qtl 1000,1578655,Bmd11,Bone mineral density QTL 11,11,,femur mineral mass (VT:0010011),total volumetric bone mineral density (CMO:0001728),4,24631874,69631874,Rat,n/a,region,qtl 1000,2300179,Bmd50,Bone mineral density QTL 50,5.9,0.0001,femur mineral mass (VT:0010011),volumetric bone mineral density (CMO:0001553),4,61975371,106975371,Rat,n/a,region,qtl 1000,5685009,Bmd86,Bone mineral density QTL 86,3.7,,tibia mineral mass (VT:1000283),bone mineral density (CMO:0001226),4,55324857,79575658,Rat,n/a,region,qtl 1000,5685012,Bmd87,Bone mineral density QTL 87,5.1,,tibia mineral mass (VT:1000283),bone mineral content (CMO:0001554),4,55324857,79575658,Rat,n/a,region,qtl 1000,631683,Bp116,Blood pressure QTL 116,,0.0001,arterial blood pressure trait (VT:2000000),systolic blood pressure (CMO:0000004),4,123111827,168111827,Rat,n/a,region,qtl 1000,631651,Bp124,Blood pressure QTL 124,3,,arterial blood pressure trait (VT:2000000),systolic blood pressure (CMO:0000004),4,63938412,108938412,Rat,n/a,region,qtl 1000,631556,Bp135,Blood pressure QTL 135,,0.017,arterial blood pressure trait (VT:2000000),mean arterial blood pressure (CMO:0000009),4,79557856,116916073,Rat,n/a,region,qtl 1000,724522,Bp146,Blood pressure QTL 146,2.2,0.0021,arterial blood pressure trait (VT:2000000),systolic blood pressure (CMO:0000004),4,75258970,120258970,Rat,n/a,region,qtl 1000,1300141,Bp178,Blood pressure QTL 178,,,arterial blood pressure trait (VT:2000000),mean arterial blood pressure (CMO:0000009),4,6572939,37703537,Rat,n/a,region,qtl 1000,1300156,Bp179,Blood pressure QTL 179,2.85,,arterial blood pressure trait (VT:2000000),mean arterial blood pressure (CMO:0000009),4,36615599,37703537,Rat,n/a,region,qtl 1000,61336,Bp21,Blood pressure QTL 21,4.6,,arterial blood pressure trait (VT:2000000),systolic blood pressure (CMO:0000004),4,55791834,79557856,Rat,n/a,region,qtl 1000,2303168,Bp330,Blood pressure QTL 330,4.25,0.017,arterial blood pressure trait (VT:2000000),mean arterial blood pressure (CMO:0000009),4,3043231,145254791,Rat,n/a,region,qtl 1000,2306899,Bp338,Blood pressure QTL 338,,0.071,arterial blood pressure trait (VT:2000000),systolic blood pressure (CMO:0000004),4,81874073,119546974,Rat,n/a,region,qtl 1000,10755501,Bp390,Blood pressure QTL 390,2.5,,arterial blood pressure trait (VT:2000000),diastolic blood pressure (CMO:0000005),4,23850384,169318094,Rat,n/a,region,qtl 1000,619616,Bp79,Blood pressure QTL 79,,0.0292,arterial blood pressure trait (VT:2000000),systolic blood pressure (CMO:0000004),4,3043231,79575658,Rat,n/a,region,qtl 1000,631546,Bp86,Blood pressure QTL 86,3.2,,arterial blood pressure trait (VT:2000000),systolic blood pressure (CMO:0000004),4,55791564,92484312,Rat,n/a,region,qtl 1000,70192,BpQTLcluster5,Blood pressure QTL cluster 5,4.183,,arterial blood pressure trait (VT:2000000),diastolic blood pressure (CMO:0000005),4,61708341,113100992,Rat,n/a,region,qtl 1000,70192,BpQTLcluster5,Blood pressure QTL cluster 5,4.183,,arterial blood pressure trait (VT:2000000),systolic blood pressure (CMO:0000004),4,61708341,113100992,Rat,n/a,region,qtl 1000,70192,BpQTLcluster5,Blood pressure QTL cluster 5,4.183,,arterial blood pressure trait (VT:2000000),mean arterial blood pressure (CMO:0000009),4,61708341,113100992,Rat,n/a,region,qtl 1000,70192,BpQTLcluster5,Blood pressure QTL cluster 5,4.183,,arterial blood pressure trait (VT:2000000),percent change in mean arterial blood pressure (CMO:0002035),4,61708341,113100992,Rat,n/a,region,qtl 1000,70192,BpQTLcluster5,Blood pressure QTL cluster 5,4.183,,arterial blood pressure trait (VT:2000000),percent change in systolic blood pressure (CMO:0000747),4,61708341,113100992,Rat,n/a,region,qtl 1000,70192,BpQTLcluster5,Blood pressure QTL cluster 5,4.183,,arterial blood pressure trait (VT:2000000),absolute change in pulse pressure (CMO:0001882),4,61708341,113100992,Rat,n/a,region,qtl 1000,70192,BpQTLcluster5,Blood pressure QTL cluster 5,4.183,,arterial blood pressure trait (VT:2000000),absolute change in mean arterial blood pressure (CMO:0000533),4,61708341,113100992,Rat,n/a,region,qtl 1000,7207480,Bss105,Bone structure and strength QTL 105,8.1,,femur strength trait (VT:0010010),femur midshaft polar moment of inertia (CMO:0001669),4,109636356,154636356,Rat,n/a,region,qtl 1000,1578657,Bss12,Bone structure and strength QTL 12,8.9,,femur morphology trait (VT:0000559),femoral neck cross-sectional area (CMO:0001697),4,56092756,101092756,Rat,n/a,region,qtl 1000,1578658,Bss13,Bone structure and strength QTL 13,8,,femur strength trait (VT:0010010),femoral neck polar moment of inertia (CMO:0001670),4,56092756,101092756,Rat,n/a,region,qtl 1000,1578670,Bss14,Bone structure and strength QTL 14,16.4,,femur morphology trait (VT:0000559),bone trabecular cross-sectional area (CMO:0002311),4,87136446,132136446,Rat,n/a,region,qtl 1000,1578662,Bss15,Bone structure and strength QTL 15,19.6,,femur width (VT:1000666),femoral neck width (CMO:0001695),4,87136446,132136446,Rat,n/a,region,qtl 1000,1549832,Bss3,Bone structure and strength QTL 3,11,,femur morphology trait (VT:0000559),femur midshaft cortical cross-sectional area (CMO:0001663),4,109636356,154636356,Rat,n/a,region,qtl 1000,4889969,Bss96,Bone structure and strength QTL 96,4.9,,tibia size trait (VT:0100001),tibia cortical bone volume (CMO:0001725),4,55324857,79575658,Rat,n/a,region,qtl 1000,4889972,Bss97,Bone structure and strength QTL 97,5.6,,tibia size trait (VT:0100001),tibia total bone volume (CMO:0001724),4,55324857,79575658,Rat,n/a,region,qtl 1000,6893678,Bw108,Body weight QTL 108,2.6,0.006,body mass (VT:0001259),body weight (CMO:0000012),4,42415777,87415777,Rat,n/a,region,qtl 1000,7394826,Bw126,Body weight QTL 126,,0.002,body mass (VT:0001259),body weight gain (CMO:0000420),4,61708103,88565113,Rat,n/a,region,qtl 1000,7411558,Bw133,Body weight QTL 133,13.84,0.001,body mass (VT:0001259),body weight gain (CMO:0000420),4,124442168,169442168,Rat,n/a,region,qtl 1000,8552801,Bw143,Body weight QTL 143,7.3,,body mass (VT:0001259),ratio of change in body weight to total body weight (CMO:0002216),4,31825560,83531021,Rat,n/a,region,qtl 1000,8552803,Bw144,Body weight QTL 144,16,,body mass (VT:0001259),ratio of change in body weight to total body weight (CMO:0002216),4,19618866,31825560,Rat,n/a,region,qtl 1000,8694374,Bw155,Body weight QTL 155,3.39,0.001,body lean mass (VT:0010483),lean tissue morphological measurement (CMO:0002184),4,8052189,53052189,Rat,n/a,region,qtl 1000,8694439,Bw168,Body weight QTL 168,9.57,0.001,retroperitoneal fat pad mass (VT:0010430),retroperitoneal fat pad weight to body weight ratio (CMO:0000635),4,39208247,84208247,Rat,n/a,region,qtl 1000,631209,Bw2,Body weight QTL2,4.2,,retroperitoneal fat pad mass (VT:0010430),retroperitoneal fat pad weight to body weight ratio (CMO:0000635),4,6467693,43414792,Rat,n/a,region,qtl 1000,70167,Bw22,Body weight QTL 22,3.1,,body mass (VT:0001259),body weight (CMO:0000012),4,77307388,116916073,Rat,n/a,region,qtl 1000,1357342,Bw40,Body weight QTL 40,,0.001,body mass (VT:0001259),body weight (CMO:0000012),4,77307388,116916073,Rat,n/a,region,qtl 1000,1549839,Bw52,Body weight QTL 52,,0.0001,body mass (VT:0001259),body weight gain (CMO:0000420),4,60439127,113416139,Rat,n/a,region,qtl 1000,1549843,Bw53,Body weight QTL 53,,0.0001,body mass (VT:0001259),body weight gain (CMO:0000420),4,60439127,99066957,Rat,n/a,region,qtl 1000,2303585,Bw86,Body weight QTL 86,4,,body mass (VT:0001259),body weight (CMO:0000012),4,12638974,57638974,Rat,n/a,region,qtl 1000,61422,Cia13,Collagen induced arthritis QTL 13,4.5,,joint integrity trait (VT:0010548),joint inflammation composite score (CMO:0000919),4,132455408,168047091,Rat,n/a,region,qtl 1000,61434,Cia3,Collagen induced arthritis QTL 3,4.8,,joint integrity trait (VT:0010548),joint inflammation composite score (CMO:0000919),4,99066823,144066823,Rat,n/a,region,qtl 1000,61451,Ciaa4,CIA Autoantibody QTL 4,3.1,,blood autoantibody amount (VT:0003725),calculated serum anti-rat type 2 collagen autoantibody titer (CMO:0001281),4,125884464,168047091,Rat,n/a,region,qtl 1000,724535,Cm18,Cardiac mass QTL 18,2.6,,heart mass (VT:0007028),calculated heart weight (CMO:0000073),4,117926139,162926139,Rat,n/a,region,qtl 1000,1641905,Colcr1,Colorectal carcinoma resistance QTL 1,4.3,0.0003,intestine integrity trait (VT:0010554),benign colorectal tumor surface area measurement (CMO:0001799),4,1,26654881,Rat,n/a,region,qtl 1000,61415,Eae11,Experimental allergic encephalomyelitis QTL 11,2.9,,nervous system integrity trait (VT:0010566),post-insult time to onset of experimental autoimmune encephalomyelitis (CMO:0001422),4,33637803,37685319,Rat,n/a,region,qtl 1000,70222,Eae2,Experimental allergic encephalomyelitis QTL 2,4.3,,nervous system integrity trait (VT:0010566),experimental autoimmune encephalomyelitis incidence/prevalence measurement (CMO:0001046),4,18222187,37685319,Rat,n/a,region,qtl 1000,2317577,Eae24,Experimental allergic encephalomyelitis QTL 24,,,nervous system integrity trait (VT:0010566),post-insult time to onset of experimental autoimmune encephalomyelitis (CMO:0001422),4,65987814,73372824,Rat,n/a,region,qtl 1000,2317577,Eae24,Experimental allergic encephalomyelitis QTL 24,,,nervous system integrity trait (VT:0010566),percentage of study population developing experimental autoimmune encephalomyelitis during a period of time (CMO:0001047),4,65987814,73372824,Rat,n/a,region,qtl 1000,2317577,Eae24,Experimental allergic encephalomyelitis QTL 24,,,nervous system integrity trait (VT:0010566),experimental autoimmune encephalomyelitis severity score (CMO:0001419),4,65987814,73372824,Rat,n/a,region,qtl 1000,2317586,Eae25,Experimental allergic encephalomyelitis QTL 25,9.300000190734863,,nervous system integrity trait (VT:0010566),experimental autoimmune encephalomyelitis severity score (CMO:0001419),4,79559380,84053053,Rat,n/a,region,qtl 1000,2317586,Eae25,Experimental allergic encephalomyelitis QTL 25,9.300000190734863,,nervous system integrity trait (VT:0010566),percentage of study population developing experimental autoimmune encephalomyelitis during a period of time (CMO:0001047),4,79559380,84053053,Rat,n/a,region,qtl 1000,2317586,Eae25,Experimental allergic encephalomyelitis QTL 25,9.300000190734863,,nervous system integrity trait (VT:0010566),post-insult time to onset of experimental autoimmune encephalomyelitis (CMO:0001422),4,79559380,84053053,Rat,n/a,region,qtl 1000,2317586,Eae25,Experimental allergic encephalomyelitis QTL 25,9.300000190734863,,nervous system integrity trait (VT:0010566),experimental autoimmune encephalomyelitis duration (CMO:0001424),4,79559380,84053053,Rat,n/a,region,qtl 1000,2317587,Eae26,Experimental allergic encephalomyelitis QTL 26,,,nervous system integrity trait (VT:0010566),experimental autoimmune encephalomyelitis severity score (CMO:0001419),4,89777552,99067150,Rat,n/a,region,qtl 1000,2317588,Eae27,Experimental allergic encephalomyelitis QTL 27,,,nervous system integrity trait (VT:0010566),percentage of study population developing experimental autoimmune encephalomyelitis during a period of time (CMO:0001047),4,99066972,110635449,Rat,n/a,region,qtl 1000,8662350,Eae35,Experimental allergic encephalomyelitis QTL 35,6.2,,blood tumor necrosis factor amount (VT:0008552),inflammatory exudate tumor necrosis factor level (CMO:0001435),4,98500164,99633958,Rat,n/a,region,qtl 1000,2306794,Ean2,Experimental allergic neuritis QTL 2,6.4,,nervous system integrity trait (VT:0010566),splenic interferon gamma-secreting mononuclear cell count (CMO:0002122),4,84475257,97479149,Rat,n/a,region,qtl 1000,61330,Eau1,Experimental allergic uveoretinitis QTL 1,,0.0003,uvea integrity trait (VT:0010551),experimental autoimmune uveitis score (CMO:0001504),4,70773471,132455556,Rat,n/a,region,qtl 1000,1576305,Emca6,Estrogen-induced mammary cancer QTL 6,5.8,,mammary gland integrity trait (VT:0010552),mammary tumor number (CMO:0000343),4,43414605,155469929,Rat,n/a,region,qtl 1000,1576316,Ept5,Estrogen-induced pituitary tumorigenesis QTL 5,3.8,,pituitary gland mass (VT:0010496),pituitary gland wet weight (CMO:0000853),4,84475257,178931073,Rat,n/a,region,qtl 1000,1354612,Foco1,Food consumption QTL 1,8.87,,eating behavior trait (VT:0001431),food intake rate (CMO:0000427),4,43414792,146942075,Rat,n/a,region,qtl 1000,2312567,Glom19,Glomerulus QTL 19,1.9,0.006,kidney glomerulus morphology trait (VT:0005325),index of glomerular damage (CMO:0001135),4,49906054,145611886,Rat,n/a,region,qtl 1000,1358202,Gluco11,Glucose level QTL 11,2.4,0.02,adipocyte glucose uptake trait (VT:0004185),absolute change in adipocyte glucose uptake (CMO:0000873),4,86438317,168047091,Rat,n/a,region,qtl 1000,1358201,Gluco12,Glucose level QTL12,1.6,,adipocyte glucose uptake trait (VT:0004185),adipocyte maximal glucose uptake (CMO:0000870),4,3044114,26753655,Rat,n/a,region,qtl 1000,61333,Gluco16,Glucose level QTL 16,4.3,,adipocyte glucose uptake trait (VT:0004185),adipocyte maximal glucose uptake to basal glucose uptake ratio (CMO:0000874),4,1,26803291,Rat,n/a,region,qtl 1000,1582232,Gluco25,Glucose level QTL 25,3.6,0.0023,blood glucose amount (VT:0000188),blood glucose level (CMO:0000046),4,86312589,146942261,Rat,n/a,region,qtl 1000,2290374,Gluco32,Glucose level QTL 32,6.27,,blood glucose amount (VT:0000188),blood glucose level area under curve (AUC) (CMO:0000350),4,35138860,43414792,Rat,n/a,region,qtl 1000,1357343,Gluco4,Glucose level QTL 4,3.1,,adipocyte glucose uptake trait (VT:0004185),adipocyte maximal glucose uptake to basal glucose uptake ratio (CMO:0000874),4,1,29778604,Rat,n/a,region,qtl 1000,2316958,Gluco58,Glucose level QTL 58,10,,blood glucose amount (VT:0000188),blood glucose level (CMO:0000046),4,7850904,182171018,Rat,n/a,region,qtl 1000,4889511,Gluco61,Glucose level QTL 61,4.7,0.001,blood glucose amount (VT:0000188),blood glucose level area under curve (AUC) (CMO:0000350),4,35138860,39073276,Rat,n/a,region,qtl 1000,634323,Hc2,Hypercalciuria QTL 2,2.15,,urine calcium amount (VT:0002985),urine calcium excretion rate (CMO:0000763),4,1,42118977,Rat,n/a,region,qtl 1000,738021,Hcar13,Hepatocarcinoma resistance QTL 13,4.3,,liver integrity trait (VT:0010547),liver nonremodeling tumorous lesion volume to total liver volume ratio (CMO:0001464),4,1,31554484,Rat,n/a,region,qtl 1000,631662,Hcar2,Hepatocarcinoma resistance QTL 2,3.1,0.0003,liver integrity trait (VT:0010547),volume of individual liver tumorous lesion (CMO:0001078),4,79555067,124555067,Rat,n/a,region,qtl 1000,634344,Hcar7,Hepatocarcinoma resistance QTL 7,7.8,,liver integrity trait (VT:0010547),liver tumorous lesion area to total liver area ratio (CMO:0001075),4,71476518,116476518,Rat,n/a,region,qtl 1000,634344,Hcar7,Hepatocarcinoma resistance QTL 7,7.8,,liver integrity trait (VT:0010547),liver tumorous lesion number (CMO:0001068),4,71476518,116476518,Rat,n/a,region,qtl 1000,634347,Hcar8,Hepatocarcinoma resistance QTL 8,5.8,,liver integrity trait (VT:0010547),liver tumorous lesion area to total liver area ratio (CMO:0001075),4,123478354,168478354,Rat,n/a,region,qtl 1000,737821,Hcar9,Hepatocarcinoma resistance QTL 9,3.7,,liver integrity trait (VT:0010547),volume of individual liver tumorous lesion (CMO:0001078),4,105971071,168047091,Rat,n/a,region,qtl 1000,1331759,Hrtrt13,Heart rate QTL 13,3.54628,,heart pumping trait (VT:2000009),heart rate (CMO:0000002),4,108876717,169215811,Rat,n/a,region,qtl 1000,1300116,Hrtrt5,Heart rate QTL 5,3.76,,heart pumping trait (VT:2000009),heart rate (CMO:0000002),4,115372758,150038284,Rat,n/a,region,qtl 1000,1300139,Hrtrt6,Heart rate QTL 6,2.85,,heart pumping trait (VT:2000009),heart rate (CMO:0000002),4,37703272,115372927,Rat,n/a,region,qtl 1000,631671,Iddm11,Insulin dependent diabetes mellitus QTL 11,3.6,0.0012,blood glucose amount (VT:0000188),plasma glucose level (CMO:0000042),4,57307075,79578854,Rat,n/a,region,qtl 1000,631674,Iddm14,Insulin dependent diabetes mellitus QTL 14,,,blood glucose amount (VT:0000188),plasma glucose level (CMO:0000042),4,63537179,157286626,Rat,n/a,region,qtl 1000,2306547,Iddm38,Insulin dependent diabetes mellitus QTL 38,,,blood glucose amount (VT:0000188),blood glucose level (CMO:0000046),4,66394000,70773654,Rat,n/a,region,qtl 1000,2306545,Iddm39,Insulin dependent diabetes mellitus QTL 39,,,blood glucose amount (VT:0000188),blood glucose level (CMO:0000046),4,78039977,78371222,Rat,n/a,region,qtl 1000,6909122,Insul22,Insulin level QTL 22,4.63,,blood insulin amount (VT:0001560),plasma insulin level (CMO:0000342),4,23991721,76238799,Rat,n/a,region,qtl 1000,2293840,Kiddil9,Kidney dilation QTL 9,2.9,,kidney pelvis morphology trait (VT:0004194),hydronephrosis severity score (CMO:0001208),4,120400597,146942261,Rat,n/a,region,qtl 1000,8655961,Kidm43,Kidney mass QTL 43,18,,kidney mass (VT:0002707),both kidneys wet weight (CMO:0000085),4,34277932,99067150,Rat,n/a,region,qtl 1000,11530004,Niddm71,Non-insulin dependent diabetes mellitus QTL 71,,0.001,blood glucose amount (VT:0000188),blood glucose level area under curve (AUC) (CMO:0000350),4,31554484,51311866,Rat,n/a,region,qtl 1000,6909128,Pancm4,Pancreatic morphology QTL 4,11.35,,pancreas mass (VT:0010144),pancreas wet weight (CMO:0000626),4,23991721,76238799,Rat,n/a,region,qtl 1000,61412,Pia2,Pristane induced arthritis QTL 2,3.9,,joint integrity trait (VT:0010548),post-insult time to onset of experimental arthritis (CMO:0001450),4,18222187,61039065,Rat,n/a,region,qtl 1000,737978,Pia23,Pristane induced arthritis QTL 23,5.3,,joint integrity trait (VT:0010548),joint inflammation composite score (CMO:0000919),4,131532269,168047091,Rat,n/a,region,qtl 1000,2302051,Pia28,Pristane induced arthritis QTL 28,5.3,0.001,blood autoantibody amount (VT:0003725),serum immunoglobulin G-type rheumatoid factor level relative to an arbitrary reference serum (CMO:0002112),4,75258970,120258970,Rat,n/a,region,qtl 1000,2302049,Pia32,Pristane induced arthritis QTL 32,5.1,0.001,blood autoantibody amount (VT:0003725),serum immunoglobulin G-type rheumatoid factor level relative to an arbitrary reference serum (CMO:0002112),4,105277348,150277348,Rat,n/a,region,qtl 1000,61418,Pia5,Pristane induced arthritis QTL 5,4.5,,joint integrity trait (VT:0010548),joint inflammation composite score (CMO:0000919),4,61038901,127777403,Rat,n/a,region,qtl 1000,631511,Pia7,Pristane induced arthritis QTL 7,4.3,,joint integrity trait (VT:0010548),joint inflammation composite score (CMO:0000919),4,131532269,168047091,Rat,n/a,region,qtl 1000,738015,Pia9,Pristane induced arthritis QTL 9,4.5,0.048,joint integrity trait (VT:0010548),joint inflammation composite score (CMO:0000919),4,76567036,121567036,Rat,n/a,region,qtl 1000,8552903,Pigfal2,Plasma insulin-like growth factor 1 level QTL 2,7.3,,blood insulin-like growth factor amount (VT:0010479),plasma insulin-like growth factor 1 level (CMO:0001299),4,1,28352196,Rat,n/a,region,qtl 1000,8552906,Pigfal3,Plasma insulin-like growth factor 1 level QTL 3,,,blood insulin-like growth factor amount (VT:0010479),plasma insulin-like growth factor 1 level (CMO:0001299),4,8052189,53052189,Rat,n/a,region,qtl 1000,724557,Plsm1,Polydactyly-luxate syndrome (PLS) morphotypes QTL 1,,0.0003,forelimb integrity trait (VT:0010562),front foot phalanges count (CMO:0001947),4,1,25545519,Rat,n/a,region,qtl 1000,724558,Plsm2,Polydactyly-luxate syndrome (PLS) morphotypes QTL 2,,0.0003,hindlimb integrity trait (VT:0010563),hind foot phalanges count (CMO:0001949),4,131834282,176834282,Rat,n/a,region,qtl 1000,2312569,Pur19,Proteinuria QTL 19,3.4,0.001,total urine protein amount (VT:0000032),urine total protein excretion rate (CMO:0000756),4,65989243,97759057,Rat,n/a,region,qtl 1000,1331807,Rf31,Renal function QTL 31,2.988,,urine potassium amount (VT:0010539),urine potassium level (CMO:0000128),4,37703272,75345433,Rat,n/a,region,qtl 1000,8655906,Rf60,Renal function QTL 60,3.8,,blood creatinine amount (VT:0005328),creatinine clearance (CMO:0000765),4,26654749,81874227,Rat,n/a,region,qtl 1000,8655949,Rf62,Renal function QTL 62,22,,blood urea nitrogen amount (VT:0005265),plasma urea nitrogen level (CMO:0000586),4,31825200,43414792,Rat,n/a,region,qtl 1000,738009,Sach4,Saccharine consumption QTL 4,4.9,0.000016,consumption behavior trait (VT:0002069),saccharin intake volume to total fluid intake volume ratio (CMO:0001601),4,58640017,154427984,Rat,n/a,region,qtl 1000,634311,Sach7,Saccharin preference QTL 7,,,taste sensitivity trait (VT:0001986),saccharin intake volume to total fluid intake volume ratio (CMO:0001601),4,55791564,82134186,Rat,n/a,region,qtl 1000,1354660,Salc1,Saline consumption QTL 1,11.26,,drinking behavior trait (VT:0001422),saline drink intake rate (CMO:0001627),4,43414792,146942075,Rat,n/a,region,qtl 1000,9589046,Scfw2,Subcutaneous fat weight QTL 2,5.54,0.001,subcutaneous adipose mass (VT:1000472),abdominal subcutaneous fat pad weight (CMO:0002069),4,1,28352196,Rat,n/a,region,qtl 1000,61408,Scl23,Serum cholesterol level QTL 23,,0.0005,blood HDL phospholipid amount (VT:0010504),serum high density lipoprotein phospholipid level (CMO:0001567),4,1,25545519,Rat,n/a,region,qtl 1000,631689,Scl4,Serum cholesterol level QTL 4,1.9,0.008,blood cholesterol amount (VT:0000180),serum total cholesterol level (CMO:0000363),4,94414208,139414208,Rat,n/a,region,qtl 1000,1549827,Scl46,Serum cholesterol level QTL 46,3.5,,blood cholesterol amount (VT:0000180),serum total cholesterol level (CMO:0000363),4,131864442,176864442,Rat,n/a,region,qtl 1000,10450818,Scl76,Serum cholesterol level QTL 76,3.6,0.01,blood VLDL cholesterol amount (VT:0005144),blood high density lipoprotein cholesterol level (CMO:0000052),4,47685694,55791834,Rat,n/a,region,qtl 1000,10450821,Scl77,Serum cholesterol level QTL 77,4.1,0.01,blood VLDL cholesterol amount (VT:0005144),blood high density lipoprotein cholesterol level (CMO:0000052),4,47685694,55791834,Rat,n/a,region,qtl 1000,10450825,Scl78,Serum cholesterol level QTL 78,3.7,0.01,blood VLDL cholesterol amount (VT:0005144),blood low density lipoprotein cholesterol level (CMO:0000053),4,47685694,55791834,Rat,n/a,region,qtl 1000,9590304,Scort17,Serum corticosterone level QTL 17,4.96,0.001,blood corticosterone amount (VT:0005345),plasma corticosterone level (CMO:0001173),4,8052189,53052189,Rat,n/a,region,qtl 1000,61406,Scwia1,Streptococcal cell wall induced arthritis QTL 1,2.3,,joint integrity trait (VT:0010548),experimental arthritis severity measurement (CMO:0001459),4,105682594,150682594,Rat,n/a,region,qtl 1000,9590100,Sffal4,Serum free fatty acids level QTL 4,7.36,0.05,blood free fatty acid amount (VT:0001553),plasma free fatty acids level (CMO:0000546),4,1,28352196,Rat,n/a,region,qtl 1000,9589097,Slep11,Serum leptin concentration QTL 11,5.09,0.001,blood leptin amount (VT:0005667),plasma leptin level (CMO:0000781),4,1,28352196,Rat,n/a,region,qtl 1000,1358363,Sradr3,Stress Responsive Adrenal Weight QTL 3,6.19,,adrenal gland mass (VT:0010420),both adrenal glands wet weight (CMO:0000164),4,58166424,103166424,Rat,n/a,region,qtl 1000,1358364,Sradr4,Stress Responsive Adrenal Weight QTL 4,4.92,,adrenal gland mass (VT:0010420),both adrenal glands wet weight (CMO:0000164),4,128602727,173602727,Rat,n/a,region,qtl 1000,1358352,Srcrt3,Stress Responsive Cort QTL 3,2.29,,blood corticosterone amount (VT:0005345),plasma corticosterone level (CMO:0001173),4,36615599,145611886,Rat,n/a,region,qtl 1000,1331802,Srn5,Serum renin concentration QTL 5,3.045,,renin activity (VT:0005581),plasma renin activity level (CMO:0000116),4,116726724,157291438,Rat,n/a,region,qtl 1000,1354665,Stl10,Serum triglyceride level QTL 10,3.57,,blood triglyceride amount (VT:0002644),serum triglyceride level (CMO:0000360),4,18222187,43414792,Rat,n/a,region,qtl 1000,1358203,Stl19,Serum triglyceride level QTL 19,2.8,0.002,blood triglyceride amount (VT:0002644),serum triglyceride level (CMO:0000360),4,3044017,64915903,Rat,n/a,region,qtl 1000,631642,Stl2,Serum triglyceride level QTL 2,3.3,,blood triglyceride amount (VT:0002644),serum triglyceride level (CMO:0000360),4,3047807,55324857,Rat,n/a,region,qtl 1000,2302371,Stl22,Serum triglyceride level QTL 22,5.15,,blood triglyceride amount (VT:0002644),serum triglyceride level (CMO:0000360),4,3044017,55791834,Rat,n/a,region,qtl 1000,631646,Stl4,Serum triglyceride level QTL 4,6.5,0.0001,blood triglyceride amount (VT:0002644),plasma triglyceride level (CMO:0000548),4,73786419,132455556,Rat,n/a,region,qtl 1000,1298082,Stresp4,Stress response QTL 4,,,blood corticosterone amount (VT:0005345),plasma corticosterone level (CMO:0001173),4,46898276,145611886,Rat,n/a,region,qtl 1000,61445,Strs3,Sensitivity to stroke QTL 3,3,,cerebrum integrity trait (VT:0010549),post-insult time to onset of cerebrovascular lesion (CMO:0002343),4,39208222,84208222,Rat,n/a,region,qtl 1000,1558651,Swd3,Spike wave discharge measurement QTL 3,4.62,0.000024,brain electrophysiology trait (VT:0010557),brain spike-and-wave discharge frequency (CMO:0001742),4,57101077,92990863,Rat,n/a,region,qtl 1000,631261,Tcas3,Tongue tumor susceptibility QTL 3,6.88,,tongue integrity trait (VT:0010553),number of squamous cell tumors of the tongue with diameter greater than 3 mm (CMO:0001950),4,7342404,92484039,Rat,n/a,region,qtl 1000,731165,Uae21,Urinary albumin excretion QTL 21,2.4,0.0001,urine albumin amount (VT:0002871),urine albumin excretion rate (CMO:0000757),4,106347236,151347236,Rat,n/a,region,qtl 1000,7387227,Uae40,Urinary albumin excretion QTL 40,2.9,0.0052,urine albumin amount (VT:0002871),urine albumin excretion rate (CMO:0000757),4,16149941,61149941,Rat,n/a,region,qtl 1000,2303623,Vencon2,Ventilatory control QTL 2,3.8,,respiration trait (VT:0001943),minute ventilation (VE) (CMO:0000132),4,134917642,179917642,Rat,n/a,region,qtl 1000,8552782,Vie1,Viral induced encephalitis QTL 1,26.4,,brain integrity trait (VT:0010579),encephalitis incidence/prevalence measurement (CMO:0002361),4,31825560,83531021,Rat,n/a,region,qtl 1000,8552807,Vie4,Viral induced encephalitis QTL 4,7.3,,brain integrity trait (VT:0010579),encephalitis incidence/prevalence measurement (CMO:0002361),4,61708341,83531021,Rat,n/a,region,qtl 1000,8552809,Vie5,Viral induced encephalitis QTL 5,25.3,,brain integrity trait (VT:0010579),encephalitis incidence/prevalence measurement (CMO:0002361),4,31825560,83531021,Rat,n/a,region,qtl 1000,70177,Xhs1,X-ray hypersensitivity QTL 1,25.1,,intestine integrity trait (VT:0010554),post-insult time to onset of moribundity (CMO:0001896),4,81959983,152055009,Rat,n/a,region,qtl 1000,634334,Xhs3,X-ray hypersensitivity QTL 3,10,,intestine integrity trait (VT:0010554),post-insult time to onset of moribundity (CMO:0001896),4,85794049,129615056,Rat,n/a,region,qtl